First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.

[1]  B. Trock,et al.  Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Terris,et al.  Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort , 2016, Prostate Cancer and Prostatic Diseases.

[3]  F. Montorsi,et al.  The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. , 2016, European urology.

[4]  M. Steinberg,et al.  Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy. , 2015, The Journal of urology.

[5]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[6]  T. Joensuu,et al.  Adjuvant Radiotherapy for Lymph‐node Positive Prostate Cancer , 2015, BJU international.

[7]  C. Rübe,et al.  Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. , 2015, International journal of radiation oncology, biology, physics.

[8]  Cesare Cozzarini,et al.  Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Blute,et al.  Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  David C. Miller,et al.  Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology , 2014 .

[11]  S. Daneshmand,et al.  Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era. , 2013, Urologic oncology.

[12]  U. Capitanio,et al.  Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. , 2013, European urology.

[13]  F. Montorsi,et al.  Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  L. Lacombe,et al.  Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy , 2013, World Journal of Urology.

[15]  O. Cussenot,et al.  Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur , 2012, World Journal of Urology.

[16]  Misop Han,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[17]  F. Montorsi,et al.  Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer. , 2010, European urology.

[18]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[19]  F. Burkhard,et al.  Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. , 2008, European urology.

[20]  Anthony V D'Amico,et al.  Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. , 2007, The Journal of urology.

[21]  E. Messing,et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.

[22]  Jorge Yao,et al.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.

[23]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[24]  B. Trock,et al.  Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. , 2004, The Journal of urology.

[25]  N. Goldstein.  Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. , 2002, American journal of clinical pathology.

[26]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[27]  P. Scardino,et al.  Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. , 2014, European urology.

[28]  S. Freedland,et al.  Role of androgen deprivation therapy for node-positive prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.